517 related articles for article (PubMed ID: 29672864)
1. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
2. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
3. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Jiménez JA; Apfelbaum AA; Hawkins AG; Svoboda LK; Kumar A; Ruiz RO; Garcia AX; Haarer E; Nwosu ZC; Bradin J; Purohit T; Chen D; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
Mol Cancer Res; 2021 Jul; 19(7):1182-1195. PubMed ID: 33741715
[TBL] [Abstract][Full Text] [Related]
4. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
[TBL] [Abstract][Full Text] [Related]
5. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium.
Kurmasheva RT; Bandyopadhyay A; Favours E; Pozo VD; Ghilu S; Phelps DA; McGeehan GM; Erickson SW; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2020 Jul; 67(7):e28284. PubMed ID: 32333633
[TBL] [Abstract][Full Text] [Related]
7. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
8. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J
Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588
[TBL] [Abstract][Full Text] [Related]
9. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
10. ATF3 promotes the serine synthesis pathway and tumor growth under dietary serine restriction.
Li X; Gracilla D; Cai L; Zhang M; Yu X; Chen X; Zhang J; Long X; Ding HF; Yan C
Cell Rep; 2021 Sep; 36(12):109706. PubMed ID: 34551291
[TBL] [Abstract][Full Text] [Related]
11. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
12. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
13. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
14. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
18. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
20. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]